Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Additional Information (Detail)

v3.8.0.1
Fair Value Measurements - Additional Information (Detail) - USD ($)
 1 Months Ended 9 Months Ended
Jun. 26, 2017
Jun. 26, 2017
Mar. 17, 2014
Sep. 30, 2017
Dec. 31, 2016
Dec. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Equity Method Investments     $ 300,000 $ 0 $ 300,000  
Equity Method Investment, Ownership Percentage     35.00%      
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease), Total       200,000    
Investment Owned, at Fair Value       $ 1,595,000 $ 2,357,000  
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 4.02 $ 4.02        
Equity Securities Called by Warrant           $ 10,000
Common Stock Par Or Stated Value Per Share       $ 0.001 $ 0.001  
Exercise Price Of Warrant Discount Percentage 33.00% 33.00%        
Debt Conversion, Converted Instrument, Shares Issued 49,749          
Investment Write down     $ 300,000      
IPO [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Stock Issued During Period, Shares, New Issues   6,325,000        
Origo Acquisition Corporation [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Investment Owned, at Fair Value       $ 900,000    
Fair Value Assumptions Probability Of Business Combination       31.40%    
Working Capital Note Convertible To Equity       $ 300,000    
National Holdings Corporation [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Percentage of Outstanding Stock To Be Issued Upon Exercise of Warrants       43.40%    
Percentage of outstanding shares, Tendered       80.00%    
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 3.25    
Warrants Not Settleable in Cash, Fair Value Disclosure       $ 5,400,000    
Debt Instrument, Face Amount $ 3,000,000 $ 3,000,000        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 125,000 125,000        
Avenue Therapeutics, Inc. [Member] | IPO [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Stock Issued During Period, Value, New Issues   $ 38,000,000        
Stock Issued During Period, Shares, New Issues   6,300,000        
Common Stock Par Or Stated Value Per Share $ 6.00 $ 6.00        
Westpark [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Class of Warrant or Right, Exercise Price of Warrants or Rights 4.02 4.02        
Common Stock Par Or Stated Value Per Share $ 6.00 $ 6.00        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 2,488 2,488        
Exercise Price Of Warrant Discount Percentage 33.00% 33.00%        
Binomial Lattice Model [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Fair Value Assumptions, Exercise Price       $ 0.33    
Binomial Lattice Model [Member] | Warrant [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Acquisition, Share Price       0.31    
Private Units [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Share Price       $ 10.61    
Argus Neurooptics Llc [Member] | Class A Preferred Stock [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Shares Received Under Purchase Agreement     $ 13,409,962      
Percentage Of Shares Received Under Purchase Agreement     83.00%      
Preferred Units, Issued     16,091,954